Scalper1 News
With a top IBD Composite Rating of 99 and four straight quarters of accelerated EPS growth, generic drug maker Akorn (AKRX) is already doing pretty well. A new analyst report outlines even more reasons to be bullish on the stock for 2015. Lake Forest, Ill.-based Akorn makes diagnostic and therapeutic ophthalmic pharmaceuticals, niche hospital drugs and injectable pharmaceuticals. Much of its attention this year has focused on a pair of high-profit Scalper1 News
Scalper1 News